| Prev Close | 72.33 |
| Day Low/High | 68.52 / 70.83 |
| 52 Wk Low/High | 60.89 / 85.97 |
Gilead Sciences, Inc. (GILD)
69.57
2.80
3.80
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 1254.37B |
| Market Cap | 90.73B |
| P/E Ratio | 18.91 |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Charting the Stocks of 3 Covid Treatment Companies
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
Gilead Sciences Is Set to Break Out: How to Play It
The stock is trading above the 50-day and the 200-day moving averages.
Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
Regeneron, PayPal, Facebook Push Up Real Money Post Industrial Average
The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.
Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
Merck Is All In With a Threefold Approach to Covid-19
I've been long Merck for a long time, since way before this pandemic became part of our lives.
Mr. Market Has Been Dead Right on General Electric
GE's problem can be summarized in one sentence: The company is burning cash.
Jim Cramer: The Hope Is Real
I get this rally -- it's based on more than a breaking branch this time, but there are still many uncertainties.
Want to Know Why I'm Not Selling Moderna?
I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.
Covering All Bases With Pfizer as It Aggressively Pursues a Covid-19 Vaccine
PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
Skating on Thin Ice, Apple and Amazon Earnings, the Price of Uncertainty
This contraction has been dramatic and unpredictable -- and best outcomes cannot be driven solely through economic creativity.
Boeing Has My Eye
This is a lower probability trade, but with the coiled price action around BA, it wouldn't take much to spring this one to life.
As Emotions Cool, Here's My Market View
My strategy here is to focus on shorter-term trades.
A Time to Plant And a Time to Pluck Up That Which Is Planted
* Mission accomplished? Sell in May and go away! * In scope and duration, stocks have rallied in a manner rarely seen in history * Month-to-date April has been the best month for equities since 1974 * The S&P Index has climbed by +31.4% since the M...
Has the Fed Eliminated the Risk of a Meaningful Pullback?
While the power of the Fed is unquestionable, there will be issues that liquidity simply can't fix.
Trading Volumes Rising, GDP Forecasts, Earnings and Trading Thoughts
Market leadership may be lacking on Thursday despite rising trading volumes, plus an update on Apple, Microsoft, Mastercard, Amazon and Gilead.
Bears Can't Make Sense of Powerful Upward Momentum
Simple logic suggests that we won't be able to deny the significant economic damage that is being done forever.
Jim Cramer: The Beginning of the End of Covid-19's Reign of Terror
There's now a much more reasonable chance the vast opening of American business won't lead to disaster.
I Believe Tesla's Earnings Will Be the Most Fun to Watch Wednesday Night
The best play post-earnings over time on Tesla has been selling bullish put spreads that expire roughly two weeks into the close TOMORROW, the first day post-earnings.
There's Nothing New in the Fed's Statement
We already know that the Fed is going to take all necessary measures to support the economy.
We Are Riding High on Hope, Not Logic
If you're looking for a longer-term market-related put play, here's something to consider.
We're All Rooting for Gilead Sciences in This Venture
I'm long GILD, but the fact is that the firm is not trying to make money off of Remdesivir at this point.
I See No Way to Put Capital to Work in a Prudent Way
What's troubling many underinvested market participants is that there really has been no acknowledgment by the market of economic issues.
Markets React to Gilead Statement
The S&P 500 and other U.S. equity futures have jumped after Gilead issued a statement saying it is aware of positive data emerging from a NIAID study of investigational antiviral remdesivir for the treatment of Covid-19. The NIAID is expected to pro...
The Market Refuses to Embrace Negatives as Major Earnings Reports Roll In
So far, earnings season has not been the obstacle that many have feared.
